


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-73 (cancelled)

Claim 74 (previously presented): A peptidomimetic of the formula:




wherein


X_1 is $(CH_2)_m$;

X_2 bearing the R_5 substituent is N and all other X_2 are CH_2 ;

R_5 is



R_6 is $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(NH_2)=NH$, $-(CH_2)_3NHCOCH_3$, $-(CH_2)_3NHCOOCH_3$,
 $-(CH_2)_2NHC(NH_2)=NH$, $-(CH_2)_2NHCONH_2$, $-(CH_2)_4NHCOH$, $-(CH_2)_4NHCOCH_3$,
 $-(CH_2)_3NHCONHCH_3$, $-(CH_2)_3NHSO_2NH_2$, $-(CH_2)_3NHCO_2CH_3$, $-(CH_2)_3NH_2$,
 $-(CH_2)_2CONH_2$, $-(CH_2)_3NH(C=NH)NHMe$, $-(CH_2)_3NH(C=NH)NHEt$,
 $-(CH_2)_3NH(C=NH)NHPr$, $-(CH_2)_3NH(C=NH)NHPr-i$, $-(CH_2)_3NH(C=NH)NH_2$,
 $-(CH_2)_4NHCONH_2$, $-(CH_2)_4NH(C=NH)NH_2$,



R₇ is R₉-R₈-;

R₈ is an L- or D-configuration of Phe, Phe(2-Cl), Phe(4-Cl), Phe(2,4-diCl), Phe(3,4-diCl), Phe(4-NO₂), Phe(4-Me), Phe(4-Phenyl), HPhe, Phg, Trp, Nal 1, Nal 2, Bip, Dip, Bpa, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), Tyr(BzlCl₂), pF-Phe, Phe(4-Br), Phe(4-CF₃), Phe(3,4-diF), Phe(4-I) or Phe(3,4-di-OMe);

R₉ is optionally not present or is an L- or D-configuration of His, Ser(Bzl), Tic, heptanoyl-Ser(Bzl), hexanoyl-Ser(Bzl), Hyp(Bzl), 4-phenylPro, 5-phenylPro, Tiq, Atc, Igl, Hyp(O-2-Naphthyl), Hyp(O-Phenyl), 2-Aic, Idc, 1-Aic, NH₂(CH₂)₆CO-, Benzyl, Beta-homoSer(Bzl), Ser(O-2-Naphthyl), Ser(O-Phenyl), Ser(O-4-Cl-Phenyl),

Ser(O-2-Cl-Phenyl), Thr(Bzl), Tic, heptanoyl-Thr(Bzl), hexanoyl-Thr(Bzl),
Beta-homoThr(Bzl), Thr(O-2-Naphthyl), Thr(O-Phenyl), Thr(O-4-Cl-Phenyl) or
Thr(O-2-Cl-Phenyl);

n is 1; and

m is 1.

Claims 75-77 (cancelled)

Claim 78 (previously presented): A pharmaceutical composition comprising the
peptidomimetic of claim 74 and a pharmaceutically acceptable carrier.

Claims 79-81 (cancelled)